Vertex Pharma stock posts Q2 growth after crossing 200-day line

Published on 10/04/2026 at 22:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock stood at USD 504.73 on October 2, 2026, with a 52-week range of USD 400.74 to USD 560.25. Q2 revenue reached USD 3.33 billion, while adjusted EPS was USD 4.73.

Aquarellbild der Boston-Skyline mit Segelbooten am Hafen im warmen Licht — Vertex Pharma US92532F1003 zeigt die Boston Skyline am Wasser in weicher Aquarell-Malerei-Optik mit Segelbooten, Illustration mit AI erstellt.

Vertex Pharma stock (ISIN US92532F1003) closed at USD 504.73 on Nasdaq on October 2, 2026, down 0.40 percent from the prior close of USD 506.74. The stock had reached USD 509.50 during the session as its 200-day moving average stood at USD 477.12, according to MarketBeat. The central question is whether the companys pipeline can extend growth beyond cystic fibrosis.

Q2 revenue rose 12.5 percent

Vertex Pharmaceuticals reported USD 3.33 billion in Q2 2026 revenue, up 12.5 percent from the prior-year quarter. The figure exceeded the USD 3.22 billion estimate, while non-GAAP EPS of USD 4.73 came in above the USD 4.72 estimate, according to Investing.com.

The latest quarter therefore combines a double-digit revenue comparison with a modest earnings beat on the non-GAAP measure. That mix matters because the share price remained USD 55.52 below the 52-week high of USD 560.25 on October 2, 2026, leaving the operating figures as the more durable part of the story.

Kidney pipeline supplies the next test

Vertex said on September 22, 2026, that inaxaplin reduced urine albumin to creatinine ratio by 42.7 percent at Week 13 in patients with APOL1-mediated kidney disease and modest proteinuria. The reduction was 17.3 percent in the cohort with type 2 diabetes, and enrollment in the Phase 2/3 AMPLITUDE trial was complete, according to the Vertex Pharmaceuticals newsroom.

The smaller diabetes-cohort reduction shows why the program still depends on later-stage confirmation. Vertex said interim AMPLITUDE results are planned for early 2027, making the kidney franchise a measurable pipeline checkpoint rather than a near-term earnings substitute.

Consensus target stays above USD 570

MarketBeat reported a Moderate Buy consensus from 23 brokerages on September 18, 2026, with an average 12-month price target of USD 570.83. Compared with the October 2 closing price of USD 504.73, that target lies 13.09 percent above the price.

The consensus sits alongside a clear execution risk: Q2 revenue growth was 12.5 percent, but investors still need clinical progress and commercialization outside the core cystic fibrosis franchise to support the broader valuation.

Vertex Pharma stock closes at USD 504.73

Vertex Pharma stock closed at USD 504.73 on Nasdaq on October 2, 2026, with a 52-week range of USD 400.74 to USD 560.25 and a market capitalization of USD 128.1 billion.